Hanx Biopharmaceuticals (3378) Announces First Patient Dosing in HX111 Phase I Clinical Trial

Bulletin Express02-04

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the “Company”) has initiated the Phase I clinical trial of HX111, an independently developed OX40-targeting antibody-drug conjugate candidate for the treatment of relapsed/refractory lymphoma and solid tumors. According to the announcement, the first patient enrollment and dosing have been successfully completed. HX111 binds to the OX40 molecule on the surface of tumor cells with high affinity and specificity. Once internalized via endocytosis, the linker is cleaved by lysosomal proteases to release a potent payload, thereby inducing tumor cell apoptosis.

The announcement emphasizes that OX40 is highly expressed in certain lymphoma and solid tumors, for which there are limited treatment options. HX111 is described as the first OX40-targeted ADC drug worldwide to publicly enter clinical trials, indicating a significant first-mover advantage in an early exploratory field. The announcement also advises caution, noting that HX111 may not ultimately be successfully developed or marketed. Shareholders and potential investors are urged to exercise prudence in any dealings related to the Company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130563360?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 21:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130563360","market":"hk","top_or_hot":-1,"title":"Hanx Biopharmaceuticals (3378) Announces First Patient Dosing in HX111 Phase I Clinical Trial","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the “Company”) has initiated the Phase I clinical trial of HX111, an independently developed OX40-targeting antibody-drug conjugate candidate for the treatment of relapsed/refractory lymphoma and solid tumors. According to the announcement, the first patient enrollment and dosing have been successfully completed. HX111 binds to the OX40 molecule on the surface of tumor cells with high affinity and specificity. Once internalized via endocytosis, the linker is cleaved by lysosomal proteases to release a potent payload, thereby inducing tumor cell apoptosis.</p>\n<p>The announcement emphasizes that OX40 is highly expressed in certain lymphoma and solid tumors, for which there are limited treatment options. HX111 is described as the first OX40-targeted ADC drug worldwide to publicly enter clinical trials, indicating a significant first-mover advantage in an early exploratory field. The announcement also advises caution, noting that HX111 may not ultimately be successfully developed or marketed. Shareholders and potential investors are urged to exercise prudence in any dealings related to the Company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanx Biopharmaceuticals (3378) Announces First Patient Dosing in HX111 Phase I Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanx Biopharmaceuticals (3378) Announces First Patient Dosing in HX111 Phase I Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-04 21:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the “Company”) has initiated the Phase I clinical trial of HX111, an independently developed OX40-targeting antibody-drug conjugate candidate for the treatment of relapsed/refractory lymphoma and solid tumors. According to the announcement, the first patient enrollment and dosing have been successfully completed. HX111 binds to the OX40 molecule on the surface of tumor cells with high affinity and specificity. Once internalized via endocytosis, the linker is cleaved by lysosomal proteases to release a potent payload, thereby inducing tumor cell apoptosis.</p>\n<p>The announcement emphasizes that OX40 is highly expressed in certain lymphoma and solid tumors, for which there are limited treatment options. HX111 is described as the first OX40-targeted ADC drug worldwide to publicly enter clinical trials, indicating a significant first-mover advantage in an early exploratory field. The announcement also advises caution, noting that HX111 may not ultimately be successfully developed or marketed. Shareholders and potential investors are urged to exercise prudence in any dealings related to the Company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1130563360","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130563360","pubTimestamp":1770210246,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the “Company”) has initiated the Phase I clinical trial of HX111, an independently developed OX40-targeting antibody-drug conjugate candidate for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"汉克斯生物制药(3378)宣布HX111 I期临床首次患者给药","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the “Company”) has initiated the Phase I clinical trial of HX111, an independently developed OX40-targeting antibody-drug conjugate candidate for the treatment of relapsed/refractory lymphoma and solid tumors. According to the announcement, the first patient enrollment and dosing have been successfully completed. HX111 binds to the OX40 molecule on the surface of tumor cells with high affinity and specificity. Once internalized via endocytosis, the linker is cleaved by lysosomal proteases to release a potent payload, thereby inducing tumor cell apoptosis.\nThe announcement emphasizes that OX40 is highly expressed in certain lymphoma and solid tumors, for which there are limited treatment options. HX111 is described as the first OX40-targeted ADC drug worldwide to publicly enter clinical trials, indicating a significant first-mover advantage in an early exploratory field. The announcement also advises caution, noting that HX111 may not ultimately be successfully developed or marketed. Shareholders and potential investors are urged to exercise prudence in any dealings related to the Company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130563360","isCrawlerRequest":true}